版本:
中国

BRIEF-Mylan says EpiPen sales suffer from increased competition

May 10 Mylan

* President says EpiPen will account for less than 5 percent of global revenue and less than 10 percent of north american sales

* President says EpiPen will account for less than 5 percent of global revenue and less than 10 percent of north american sales in 2017 (adds year)

* Says still expects profits from EpiPen to be down $400 million in 2017 from last year Further company coverage: (Reporting By Michael Erman)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐